Shannon N. Westin, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the DUO-E/GOG-3041/ENGOT-EN10 (NCT04269200) trial, a randomized, Phase III trial evaluated the combination of immunotherapy with chemotherapy (CP) for patients with advanced endometrial cancer (EC). The trial included three treatment arms: CP, CP with durvalumab (CP + durva), and CP with durvalumab and olaparib (CP + durva + ola). The primary endpoints were progression-free survival (PFS) for CP + durva vs. CP and CP + durva + ola vs. CP. The results showed statistically significant and clinically meaningful improvements in PFS for both combination arms compared to CP alone. Interim overall-survival (OS) data indicated a trend towards benefit. Subgroup analysis demonstrated benefits for both mismatch repair-deficient (dMMR) and -proficient (pMMR) patients, with additional PFS improvement in pMMR patients receiving olaparib. The study supports the use of these combination therapies in EC.Dr Westin elaborates on the exciting amelioration of outcomes for mismatch repair proficient patients who received doublet maintenance therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
